Dr. William J. Polvino, M.D.
President and Chief Executive Officer

Dr. William Polvino, M.D.

Dr. Polvino joined Veloxis in September 2009 bringing extensive experience in the senior management of pharmaceutical companies together with solid operational experience in drug development and specialty pharma strategy.   Earlier in his career, Dr. Polvino was CEO at Helsinn Therapeutics US, Inc (a private company), formerly Sapphire Therapeutics. At Sapphire, he helped drive novel in-licensed new chemical entities into late-stage clinical development, successfully leading the company through acquisition to Helsinn Therapeutics US in January 2009. 

Dr. Polvino began his career in the life science industry following his professional training in Internal Medicine at Massachusetts General Hospital and his fellowship in Clinical Pharmacology at the National Institute of Health, USA.   

Dr. Polvino has held various senior positions of increasing responsibility within drug development and executive functions at Merck, Wyeth and Theravance prior to joining Sapphire Therapeutics in 2002.  Dr. Polvino holds six issued US patents and corresponding international counterparts.

Johnny Stilou
Executive Vice President, Chief Financial Officer

Johnny Stilou

Mr. Stilou joined Veloxis in April 2008. He is responsible for the activities within Finance, IT, Legal Affairs, and Investor Relations.

Prior to joining Veloxis, Mr. Stilou held a number of CFO positions with international technology and Medicare companies.

Mr. Stilou began his career with KPMG in Denmark in 1986. From 1995, he held various senior finance positions within the GN Great Nordic group until 2003.

Mr. Stilou holds a Master of Science in Economics and Business Administration from the Copenhagen Business School.

Dr. John Weinberg
Executive Vice President, Chief Operating Officer

John Weinberg

Dr. Weinberg joined Veloxis in July 2010. He is responsible for managing all Commercial activities supporting the Veloxis portfolio of compounds in development. Additionally, Dr. Weinberg directs Corporate Strategy and Pipeline Target Identification.

Prior to joining Veloxis, Dr. Weinberg was Business Franchise Head at Novartis Pharmaceuticals Corporation in the transplant and infectious disease business unit. In this capacity, he successfully managed and grew the US Transplant business.

Earlier in his career, Dr. Weinberg served as Oncology Business Unit Head at Enzon Pharmaceuticals, Inc, from 2003 to 2005. From 1996 to 2003, Dr. Weinberg held various positions of increasing responsibility within the Global Marketing function at Wyeth Pharmaceuticals, successfully managing brands across multiple therapeutic areas, including oncology, hematology, transplantation, and autoimmune diseases.

Dr. Weinberg received his MD degree from the University of the Witwatersrand School of Medicine, Johannesburg, South Africa, and his MBA degree from INSEAD in Fontainebleau, France.

Christina Sylvest
Senior Vice President, Global Clinical Development & Operations

Christina Sylvest

Ms. Sylvest joined Veloxis in April 2008. She is responsible for clinical development, clinical operations and drug supply.

Ms. Sylvest has extensive experience in conducting global clinical studies both within the pharmaceutical industry and the CRO business. Prior to joining Veloxis, Mrs. Sylvest held the position as director of clinical operations at Rheoscience A/S, where she established the clinical operations department and led the execution and management of the company's clinical studies. She was a member of the management team and involved in establishing the company strategy.

Prior positions for Ms. Sylvest include global project management responsibility at Quintiles A/S and establishment of the NovoSeven® clinical operations surgery group at Novo Nordisk A/S.

Ms. Sylvest holds an MSc in pharmacy from the Pharmaceutical University of Copenhagen.

Mr. Breian Knudsen
Vice President, Technical Operations

Mr. Knudsen joined Veloxis in November 2007. He is responsible for technology transfer, process validation, clinical and commercial manufacturing.

Mr. Knudsen has an extensive experience within process and product development, technology transfer, process validation and manufacture within the pharmaceutical industry.

Prior to joining Veloxis, Mr. Knudsen held a position as Principal Scientist, Chemistry Manufacturing & Controls (CMC) project manager at Novo Nordisk A/S where he headed the CMC part of a number of solid dosage development projects and where he implemented guidelines for systematic in-house and external transfer of manufacturing processes.

Mr. Knudsen holds an MSc in pharmacy from the Pharmaceutical University of Copenhagen.

Michelle McGuinness
Vice President, Global Regulatory Affairs & QA

Michelle McGuinness

Ms. Mc Guinness is joined Veloxis in May 2014 bringing 15+ years of experience in regulatory, quality and compliance roles within the pharmaceutical industry.   Prior to joining Veloxis, Ms. Mc Guinness held the position of Senior Director of Regulatory Conformance at Mylan, where she established the global regulatory conformance function and team, deployed global processes and systems, and drove strategic regulatory, quality and compliance projects.  Prior to joining Mylan, Ms. Mc Guinness held various positions of increasing responsibility at PA Consulting, Accenture (formerly Octagon Research Solutions), Sanofi, Liquent (a Paraxel company) and Ranbaxy Pharmaceuticals Inc.

Ms. Mc Guinness has participated in a number of joint industry-agency initiatives.  She was awarded the FDA Commissioner’s Special Citation for her contribution the development of the HL7 Structured Product Labeling standard & FDA guidance.

Ms. Mc Guinness holds an MSc in Quality Assurance/Regulatory Affairs from the Temple University School of Pharmacy.  She holds a BA in Biology-Biotechnology from Kean University and is RAC-US certified.

Ms. Mc Guinness is passionate about supporting the rare diseases and orphan indication communities.  She volunteers as a director of the Southeastern PA Chapter of Huntington’s Disease Society of America (HDSA) and is a scientific advisor for the CADASIL Association.